MITHRAMYCIN A
- CAS No.
- 18378-89-7
- Chemical Name:
- MITHRAMYCIN A
- Synonyms
- MITHRAMYCIN;PLICAMYCIN;2371;pa144;mitramycin;a-2371;nsc24559;MITHRACIN;luteomycin;aurelicacid
- CBNumber:
- CB9127380
- Molecular Formula:
- C52H76O24
- Molecular Weight:
- 1085.15
- MDL Number:
- MFCD00135618
- MOL File:
- 18378-89-7.mol
- MSDS File:
- SDS
| Melting point | 180-183 °C |
|---|---|
| alpha | D20 -51° (c = 0.4 in ethanol) |
| Boiling point | 761.72°C (rough estimate) |
| Density | 1.1576 (rough estimate) |
| refractive index | 1.6500 (estimate) |
| storage temp. | 2-8°C |
| solubility | Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 10 mg/ml) |
| form | Powder |
| pka | 4.54±0.60(Predicted) |
| color | Red to brown |
| Merck | 13,7619 |
| BRN | 5236667 |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. |
| EWG's Food Scores | 1 |
| NCI Dictionary of Cancer Terms | Mithracin; mithramycin; plicamycin |
| FDA UNII | NIJ123W41V |
| NCI Drug Dictionary | Mithracin |
| ATC code | L01DC02 |
| Proposition 65 List | Plicamycin |
| EPA Substance Registry System | Plicamycin (18378-89-7) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P301+P312+P330 | |||||||||
| Hazard Codes | Xn,T+ | |||||||||
| Risk Statements | 22-26/27/28 | |||||||||
| Safety Statements | 45-38-36/37/39-28A-22 | |||||||||
| RIDADR | 3249 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | PZ2800000 | |||||||||
| F | 10 | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 29419090 | |||||||||
| Toxicity | LD50 in mice, rats (mg/kg): 2.14, 1.74 i.v. (Slavik, Carter) | |||||||||
| NFPA 704 |
|
MITHRAMYCIN A price More Price(17)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | M6891 | Mithramycin A from Streptomyces plicatus ≥90% (HPLC) | 18378-89-7 | 1mg | $204 | 2024-03-01 | Buy |
| Sigma-Aldrich | M6891 | Mithramycin A from Streptomyces plicatus ≥90% (HPLC) | 18378-89-7 | 5mg | $855 | 2024-03-01 | Buy |
| Sigma-Aldrich | 5.30310 | Mithramycin A - CAS 18378-89-7 - Calbiochem | 18378-89-7 | 2mg | $166 | 2022-05-15 | Buy |
| Alfa Aesar | J67319 | Plicamycin, 1 mg/ml in DMSO, sterile-filtered | 18378-89-7 | 1ml | $268 | 2023-06-20 | Buy |
| Cayman Chemical | 11434 | Mithramycin A ≥98% | 18378-89-7 | 1mg | $49 | 2024-03-01 | Buy |
MITHRAMYCIN A Chemical Properties,Uses,Production
Description
Mithramycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It is well known as the aureolic acid antitumor antibiotic that inhibits both cancer growth and bone resorption by cross-linking GC-rich DNA, thus blocking binding of Sp-family transcription factors to gene regulatory elements. Transcription of c-Src, a gene implicated in many human cancers and required for osteoclast-dependent bone resorption, is regulated by the binding of Sp factors to specific elements in its promoter. Therefore, this gene represents an important anticancer target and a potential lead target through which mithramycin displays action against osteoclastic bone resorption via an unknown mechanism. Hazards of handling this drug by the health-care personnel arise from a combination of factors: (1) its inherent toxicity and (2) the extent to which workers are exposed to the drug in the course of carrying out their duties. This exposure may be through inadvertent ingestion of the drug on foodstuffs (e.g., workers’ lunches), inhalation of drug dusts or droplets, or direct skin contact. Mithramycin has been used to decrease bone resorption in patients with humoral hypercalcemia and Paget’s disease.
Chemical Properties
yellow powder
Uses
Mithramycin was the first of the aureolic acid class of antitumour antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts.
Uses
Transcription inhibitor
Uses
Mithramycin A was the first of the aureolic acid class of antitumor antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts.
Indications
Plicamycin (mithramycin, Mithracin) is one of the chromomycin group of antibiotics produced by Streptomyces tanashiensis. Plicamycin binds to DNA and inhibits transcription. It also inhibits resorption of bone by osteoblasts, thus lowering serum calcium levels.Very little is known about its distribution, metabolism, and excretion. Because of its severe toxicity, plicamycin has limited clinical utility.The major indication for plicamycin therapy is in the treatment of life-threatening hypercalcemia associated with malignancy. Plicamycin also can be used in the palliative therapy of metastatic testicular carcinoma when all other known active drugs have failed.
Definition
ChEBI: Mithramycin is a carbohydrate-containing antibiotic, an anthracycline antibiotic, an aureolic acid and a secondary alpha-hydroxy ketone. It has a role as an antineoplastic agent, an EC 2.7.7.6 (RNA polymerase) inhibitor and a metabolite.
Application
Mithramycin, recently renamed plicamycin, was found in the culture broth of Streptomyces argillaceus and S. tanashiensis by Abbott Laboratories in 1952. It is structurally related to chromomycin A3. Mithramycin shows strong inhibitory activity against malignant cells of human origin. It acts by inhibition of the DNA-directed RNA synthesis through binding with DNA. Mithramycin is used intravenously to treat cancers of the embryonal cells, seminoma, choriocarcinoma, etc.
brand name
Mithracin (Pfizer) [Name previously used: Mithramycin.].
General Description
Chemical structure: aureolic acid
Biological Activity
Anticancer antibiotic that selectively binds to G-C-rich DNA in the presence of Mg 2+ or Zn 2+ , inhibiting RNA and DNA polymerase action. Inhibits c-myc expression and induces myeloid differentiation of HL-60 promyelocytic leukemia cells.
Biochem/physiol Actions
Anticancer antibiotic. Inhibits transcription and protein synthesis. Binds to DNA in native chromatin. Substrate of Pgp in MDR phenotypes.
storage
Store at -20°C
Purification Methods
Purify mithramycin A by crystallisation from CHCl3. It is soluble in MeOH, EtOH, Me2CO, EtOAc, Me2SO and H2O, and moderately soluble in CHCl3, but is slightly soluble in *C6H6 and Et2O. It is a fluorescent antitumour agent used in flow cytometry. [Thiem & Meyer Tetrahedron 37 551 1981, NMR: Yu et al. Nature 218 193 1968, Beilstein 17/1 V 672.]
Toxicity evaluation
Mithramycin inhibits mRNA and protein synthesis by adhering to DNA. Mithramycin appears to affect bone resorption by stimulating osteoclast activity and results in hypocalcemia and hypophosphatemia. It is believed to lower serum calcium concentrations, but the exact mechanism is unknown. It may act by blocking hypercalcemic action of vitamin D or by inhibiting the effect of parathyroid hormone on osteoclasts. Its inhibition of DNA-dependent RNA synthesis appears to render osteoclasts unable to fully respond to parathyroid hormone with the biosynthesis necessary for osteolysis.
References
1) Lin?et al. (2007),?Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells; Anticancer Drugs,?18?1157 2) Jia?et al.?(2010),?Combined treatment of pancreatic cancer cells with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic anti-tumor activity; Cancer Res.,?70?1111 3) Lee?et al. (2006),?Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites; Mol. Cancer Ther.,?5?2737
MITHRAMYCIN A Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hebei Mojin Biotechnology Co., Ltd | +8613288715578 | sales@hbmojin.com | China | 12456 | 58 |
| career henan chemical co | +86-0371-86658258 | sales@coreychem.com | China | 29914 | 58 |
| Hebei Guanlang Biotechnology Co., Ltd. | +86-19930503282 | alice@crovellbio.com | China | 8823 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| Chongqing Chemdad Co., Ltd | +86-023-61398051 +8613650506873 | sales@chemdad.com | China | 39916 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-29-87569266 15319487004 | 1015@dideu.com | China | 2263 | 58 |
| Fuxin Pharmaceutical | +86-021-021-50872116 +8613122107989 | contact@fuxinpharm.com | China | 10297 | 58 |
| SHANGHAI T&W PHARMACEUTICAL CO., LTD. | +86-021-61551413 +8618813727289 | contact@trustwe.com | China | 5738 | 58 |
| Zhejiang Huida Biotech Co., LTD | 008613515763466 8615669048680 | wendy@huidabiotech.com | CHINA | 87 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
View Lastest Price from MITHRAMYCIN A manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2023-07-04 | MITHRAMYCIN A
18378-89-7
|
US $0.00 / KG | 1KG | 99% | 50000KG/month | Hebei Mojin Biotechnology Co., Ltd | |
 |
2021-07-02 | MITHRAMYCIN A USP/EP/BP
18378-89-7
|
US $1.10 / g | 1g | 99.9% | 100 Tons Min | Dideu Industries Group Limited | |
 |
2021-05-25 | MITHRAMYCIN A
18378-89-7
|
US $1.00 / PCS | 1KG | 99% | 10 mt | Hebei Guanlang Biotechnology Co., Ltd. |
-
- MITHRAMYCIN A
18378-89-7
- US $0.00 / KG
- 99%
- Hebei Mojin Biotechnology Co., Ltd
-
- MITHRAMYCIN A USP/EP/BP
18378-89-7
- US $1.10 / g
- 99.9%
- Dideu Industries Group Limited
-
- MITHRAMYCIN A
18378-89-7
- US $1.00 / PCS
- 99%
- Hebei Guanlang Biotechnology Co., Ltd.
18378-89-7(MITHRAMYCIN A)Related Search:
1of4